Floatz logo

Therapeutic Asset Ratings

178 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
DIPHTHERIA TOXOID
Multiple Sclerosis
CelgeneP3CCC (54)
FENTANYL
Multiple Sclerosis
University of MiamiP3CCC (54)
Ketorolac Tromethamine
Multiple Sclerosis
University of MiamiP3CCC (54)
Siponimod
Multiple Sclerosis
Novartis PharmaceuticalsP3CCC (54)
Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine
Multiple Sclerosis
CelgeneP3CCC (54)
Busulphan
Multiple Sclerosis
Stanford UniversityP2CCC (54)
Mesna
Multiple Sclerosis
Indapta Therapeutics, INC.P2CCC (54)
Ublituximab
Multiple Sclerosis
TG Therapeutics, Inc.P4CCC (52)
Activated Charcoal
Multiple Sclerosis
SanofiP3CCC (52)
Adezunap
Multiple Sclerosis
Apurano Pharmaceuticals GmbHP3CCC (52)
HYDROMORPHON
Multiple Sclerosis
University of MiamiP3CCC (52)
Anti-Thymoglobulin, Rabbit
Multiple Sclerosis
Fred Hutchinson Cancer CenterP2CCC (52)
Folic Acid
Multiple Sclerosis
University of MiamiP2CCC (52)
Kyv-101
Multiple Sclerosis
Kyverna TherapeuticsP2CCC (52)
Letrozole
Multiple Sclerosis
State University of New York at BuffaloP2CCC (52)
N-Acetyl-L-Cysteine
Multiple Sclerosis
Emmanuelle Waubant, MD PhDP2CCC (52)
Tolerogenic Dendritic Cells
Multiple Sclerosis
University Hospital, AntwerpP2CCC (52)
Zinc
Multiple Sclerosis
University of MiamiP2CCC (52)
Adderall Xr
Multiple Sclerosis
Sarah MorrowP2/3CCC (52)
Allogeneic Adipose-Derived Mesenchymal Stem Cells
Multiple Sclerosis
Hope Biosciences Research FoundationP2CCC (51)
MODERNA COVID-19 VACCINE RNA
Multiple Sclerosis
Griffin HospitalP2CCC (51)
Rvp-001
Multiple Sclerosis
Reveal Pharmaceuticals Inc.P2CCC (51)
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION
Multiple Sclerosis
Institute of Psychiatry and Neurology, WarsawP2/3CCC (49)
11C-MC1
Multiple Sclerosis
National Institute of Mental Health (NIMH)P2CCC (48)
18F-ASIS
Multiple Sclerosis
Mayo ClinicP2CCC (48)
Showing 51 to 75 of 178 assets
PreviousPage 3 of 8Next